Radiolabeled biomolecules for early cancer detection and therapy via angiogenesis targeting

Bouziotis, P; Psimadas, D; Fani, M; Gourni, E; Loudos, G; Xanthopoulos, S; Archimandritis, SC; Varvarigou, AD

dc.contributor.author	Bouziotis, P	en
dc.contributor.author	Psimadas, D	en
dc.contributor.author	Fani, M	en
dc.contributor.author	Gourni, E	en
dc.contributor.author	Loudos, G	en
dc.contributor.author	Xanthopoulos, S	en
dc.contributor.author	Archimandritis, SC	en
dc.contributor.author	Varvarigou, AD	en
dc.date.accessioned	2014-03-01T01:24:58Z
dc.date.available	2014-03-01T01:24:58Z
dc.date.issued	2006	en
dc.identifier.issn	0168-9002	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/17511
dc.subject	Angiogenesis	en
dc.subject	Antiangiogenic treatment	en
dc.subject	Integrins	en
dc.subject	RGD peptides	en
dc.subject	VEGF	en
dc.subject.classification	Instruments & Instrumentation	en
dc.subject.classification	Nuclear Science & Technology	en
dc.subject.classification	Physics, Particles & Fields	en
dc.subject.classification	Spectroscopy	en
dc.subject.other	Amino acids	en
dc.subject.other	Antibodies	en
dc.subject.other	Blood vessels	en
dc.subject.other	Cells	en
dc.subject.other	Isotopes	en
dc.subject.other	Tumors	en
dc.subject.other	Angiogenesis	en
dc.subject.other	Antiangiogenic treatment	en
dc.subject.other	Integrins	en
dc.subject.other	RGD peptides	en
dc.subject.other	Radiotherapy	en
dc.title	Radiolabeled biomolecules for early cancer detection and therapy via angiogenesis targeting	en
heal.type	journalArticle	en
heal.identifier.primary	10.1016/j.nima.2006.08.142	en
heal.identifier.secondary	http://dx.doi.org/10.1016/j.nima.2006.08.142	en
heal.language	English	en
heal.publicationDate	2006	en
heal.abstract	Tumors cannot grow or metastasize without the formation of new blood vessels, i.e. without angiogenesis. A variety of anti-angiogenic agents leading to angiogenesis inhibition are in the clinical trial phase, among which are: (i) molecules which inhibit the action of Vascular Endothelial Growth Factors, VEGF and (ii) molecules which obstruct migration, differentiation and proliferation of endothelial cells, via their binding to receptors of the alpha(nu)beta(3) integrins. Certain derivatives of the abovementioned categories, labeled with radionuclides, which emit gamma-radiation or beta-particles or positrons, have been proposed and are being evaluated as possible radiopharmaceuticals, for the detection and/or treatment of primary or metastatic cancer at an early stage. For the study of angiogenesis the following have been described: (a) antibodies targeting VEGF, labeled with radionuclides emitting beta- and/or gamma-radiation, which can be applied for the diagnosis and, possibly, for the treatment of cancer, (b) peptide derivatives which contain the amino-acid sequence RGD (Arg-Gly-Asp) and compete for the alpha(nu)beta(3) integrins, with the proteins of the stroma. It has been found that these radiolabeled biomolecules localize in tumors and can be used for the visualization and, possibly, for tumor eradication of primary and metastatic cancer. In our laboratory radiolabeling of biomolecules by beta and/or gamma emitters is a principal research goal. In the present work we are presenting our results on the labeling of monoclonal antibodies and peptides with beta- and gamma-emitting isotopes, as well as on their in vivo evaluation in experimental animal models, by use of specially dedicated imaging devices. (c) 2006 Elsevier B.V. All rights reserved.	en
heal.publisher	ELSEVIER SCIENCE BV	en
heal.journalName	Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment	en
dc.identifier.doi	10.1016/j.nima.2006.08.142	en
dc.identifier.isi	ISI:000243241300075	en
dc.identifier.volume	569	en
dc.identifier.issue	2 SPEC. ISS.	en
dc.identifier.spage	492	en
dc.identifier.epage	496	en